Weight loss jabs such as Mounjaro linked to lower dementia and stroke risk
Academics said the benefits of drugs such as Wegovy and Mounjaro – including for managing weight and blood sugar levels – are well known, but other health benefits of the popular drugs remain 'unclear'.
People with type 2 diabetes and obesity who are taking the drugs are also less likely to die prematurely, researchers found.
The study saw experts from Taiwan examine date on 60,000 people from around the world, with an average age of 58, who had type 2 diabetes and obesity.
Key differences between three weight-loss injections: Mounjaro, Wegovy, and Ozempic. https://t.co/WhHodrztS1 pic.twitter.com/Rll5Eg3ycU
— Paul Wischmeyer MD (@Paul_Wischmeyer) July 4, 2025
Around half were given GLP agonist drugs semaglutide and tirzepatide – which are sold under the brand names Wegovy and Mounjaro. Semaglutide is also the main ingredient for the type 2 diabetes drug Ozempic.
GLP agonists can reduce a person's appetite; slow down their digestion; reduce the amount of sugar the liver makes and they help the body to make more insulin when needed.
The other half used other anti-diabetic medication.
📢Important update Eligible people in #Dorset will be able to access Tirzepatide (Mounjaro) weight management medication from autumn 2025. ✅Around 1,000 people in Dorset will qualify under strict national criteria ✅No need to contact your doctor More: https://t.co/ml4QJgZ224 pic.twitter.com/uURpuIuYzx
— NHS Dorset (@NHSDorset) June 23, 2025
During a seven-year follow-up period, researchers found that people given the GLP agonist drugs appeared to have a 37% lower risk of dementia and a 19% reduced risk of stroke.
They were also 30% less likely to die during the follow-up period.
And when researchers looked at the data further they found even greater benefits in people aged 60 or older, women, and those with a body mass index score of 30 to 40.
They found no differences in Parkinson's disease or brain bleeds.
The academics said their findings suggest 'potential neuroprotective and cerebrovascular benefits' of the drugs but they called for more studies to confirm the findings.
Recommended reading:
Mounjaro sales adverts banned by watchdog
Mounjaro patients report unexpected side-effect
Who is eligible for free Mounjaro on the NHS?
'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,' they wrote in the journal JAMA Network Open.
Commenting on the study, Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh and group leader in the UK Dementia Research Institute, said: 'This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity.
'This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain.
'It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions.
'Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity.'
Recommended reading:
When will Mounjaro be rolled out on the NHS?
Travel insurance warning about certain types of policy
Warning as Mounjaro and Ozempic sold without prescription
Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, said: 'It is well established that diabetes and obesity can increase your risk of developing dementia.
'This study supports existing evidence that shows these drugs may reduce dementia risk, particularly for people aged 60 and over who are living with type 2 diabetes and obesity.
'Although interesting, we can't draw conclusions from this study alone as it is an observational study, only a small number of people who took part went on to develop dementia and as the impact of these drugs on different types of dementia is not clear.
'There are clinical trials currently looking at whether drugs like these can be used to treat early-stage Alzheimer's disease, so this is a really exciting area being explored in the research fight against dementia.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
The best and worst GPs in your area of Greater Manchester, according to patients
Patients in Greater Manchester have had their say on doctor's surgeries in the region. More than 2.7 million people across the country took part in this year's GP Patient Survey, which finds out how people feel about their GP practice. The annual survey asks people about their last contact, your last appointment and overall experience with their surgery. READ MORE: Man flouts 'no sex' advice after hair transplant and ends up regretting it READ MORE: Child dies in hospital after contracting measles - symptoms to look out for The questionnaire also includes questions about when your GP practice is closed, your health, pharmacy and NHS dentistry services. Never miss a story with the MEN's daily Catch Up newsletter - get it in your inbox by signing up here The results, published by Ipsos on behalf of NHS England, reveal the surgeries in our region with the highest and lowest rating. You can see how your practice has fared in the survey using our interactive. Simply enter the name of the GP surgery in the search box and select it from the dropdown. Marple Bridge Surgery in Stockport came out on top, with 99% of those surveyed saying their overall experience was 'good.' Second was Riddings Family Health Centre in Timperley where 98% agreed. Zaman at Worsley Mesnes Health Centre in Wigan also received 98%, as did the Premier Health Team at Bridgewater Medical Centre, in Leigh. Whilst Milnrow Village Practice received 97%. Join the Manchester Evening News WhatsApp group HERE Lees Medical Practice in Oldham received the lowest rating, with just 33% of those surveyed describing their overall experience as 'good.' They were followed by Hattersley Group Practice with 41%. Ashton Medical Group in Tameside got 45, as did the Croft Shifa Health Centre in Rochdale. However, some of the results are not based on large sample sizes. For example, the response rate at Zaman and Premier Health, rated highly, was just 36% and 26% respectively. Whilst the response at the lower ranked Lees, Hattersley, Ashton, and Croft Shifa was 24%, 22%, 22% and 11% respectively. Nationally, the majority of people seem happy with the service offered, with 75% rating the overall experience as either 'very good' or 'fairly good.' Only seven percent said 'fairly poor' and five percent said 'very poor.' The overwhelming majority of patients surveyed (93%), said that they had confidence and trust in their GP. Some 86% say their GP treats them with care and concern, and 87% say their GP listens to them. GP practices didn't fare as well though when it comes to being contacted. Only just over half (53%) of those surveyed said that contacting their GP was easy. Satisfaction varies across practices. Lowest ranked GM practices Highest ranked GM practices
The Hill
3 hours ago
- The Hill
Weight loss drugs may lower risk of dementia, stroke: Study
Some popular weight loss drugs may lower the risk of dementia and stroke for patients with Type 2 diabetes and obesity, new research published in JAMA Network suggests. Patients taking semaglutide or tirzepatide medications — active ingredients in weight loss drugs such as Ozempic, Mounjaro and Wegovy — showed a lower risk of developing certain diseases compared to those taking other, similar medications. Those include neurodegenerative diseases, such as dementia and Alzheimer's, and cerebrovascular disease, which manifests in strokes, brain aneurysms and more. Researchers analyzed the health developments over seven years in 60,000 adults aged 40 or older diagnosed with both Type 2 diabetes and obesity, as recorded by the TriNetX U.S. network. The patients were all users of semaglutide, tirzepatide or other GLP-1 anti-diabetes drugs from December 2017 through June 2024. The effects were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40. Researchers acknowledged more clinical trials are needed to corroborate their initial findings, but they maintained the data 'represents one of the most recent clinical database–driven analyses to investigate the neuroprotective and cerebrovascular associations of newer GLP-1RAs' for some patients.
Yahoo
3 hours ago
- Yahoo
Physician associates should ‘never be used to replace doctors'
Patient safety will be at the forefront of changes to the roles of NHS physician associates (PAs), who should 'never be used to replace doctors', the Health Secretary has said. Wes Streeting pledged to implement in full the findings of a review which said PAs must not diagnose patients when they come into A&E or GP practices and must be renamed as 'physician assistants'. Mr Streeting ordered the review into PAs and anaesthesia associates (AAs) after concerns were raised over whether they were safe and the impact on the training of junior doctors. The review, chaired by Professor Gillian Leng, who is president of the Royal Society of Medicine, made 18 recommendations. Mr Streeting said: 'Patients should always know who they are being treated by and should always receive appropriate care. 'Legitimate concerns about patient safety have been ignored for too long – that's why I sought out the very best clinical advice to review physician associates and anaesthesia associates' roles in the NHS. 'We're accepting all of the recommendations of the Leng review, which will provide clarity for the public and make sure we've got the right staff, in the right place, doing the right thing. Patients can be confident that those who treat them are qualified to do so. 'Physician assistants, as they will now be known, will continue to play an important role in the NHS. They should assist doctors, but they should never be used to replace doctors.' Prof Leng's review suggested a major change to the role of PAs after it acknowledged they have been used as substitutes for doctors, despite having significantly less training. More than 3,500 PAs and 100 anaesthesia associates (AAs) are working in the NHS and there have been previous calls for an expansion in their number. But a general lack of support for both roles from the medical profession – plus high-profile deaths of patients who were misdiagnosed by PAs – led to the review. Presenting her findings, Prof Leng said: 'Crucially I'm recommending that PAs should not see undifferentiated or untriaged patients. 'If (patients) are triaged, they (PAs) should be able to see adult patients with minor ailments in line with relevant guidance from the Royal College of GPs.' She said more detail was needed on which patients can be seen by PAs and national clinical protocols will now be developed in this area. She added: 'Let's be clear, (the role of PAs) is working well in some places, but there indeed has been some substitution and any substitution is clearly risky and confusing for patients.' Newly qualified PAs will also now work in hospitals for two years before they are allowed to work in GP surgeries or mental health trusts. The study said safety concerns in relation to PAs were 'almost always about making a diagnosis and deciding the initial treatment, particularly in primary care or the emergency department, where patients first present with new symptoms'. It added: 'It is here that the risk of missing an unusual disease or condition is highest, and where the more extensive training of doctors across a breadth of specialties is important. 'Making the wrong initial diagnosis and putting patients on an inappropriate pathway can be catastrophic.' Despite the shorter two years of training for PAs, where local NHS services have struggled with filling roles, 'the easy option in some cases was simply to fill gaps in medical rotas with PAs', the report went on. When it comes to the safety of PAs and AAs, Prof Leng said the 'evidence is poor', with 'no compelling evidence' in published research 'that PAs were safe to work as doctor substitutes in primary care'. Prof Leng concluded there were 'no convincing reasons to abolish the roles of AA or PA' but there is also no case 'for continuing with the roles unchanged'. She recommended that both PAs and AAs should have the opportunity for ongoing training and development, with potential to prescribe medicines in the future, and they should also should have the opportunity to become an 'advanced' PA or AA. Six patient deaths linked to contact with PAs have been recorded by coroners in England. One high-profile death involved Emily Chesterton, 30, who died from a pulmonary embolism. She was misdiagnosed by a PA on two occasions and told she had anxiety. NHS England has written to NHS trusts setting out the new changes, saying PAs currently working in primary care, emergency departments or any other setting must not triage patients or see undifferentiated patients without a diagnosis.
